Free Trial
NASDAQ:CTSO

Cytosorbents (CTSO) Stock Price, News & Analysis

Cytosorbents logo
$1.04 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.02 -0.02 (-1.44%)
As of 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cytosorbents Stock (NASDAQ:CTSO)

Key Stats

Today's Range
$1.00
$1.07
50-Day Range
$0.81
$1.08
52-Week Range
$0.70
$1.59
Volume
56,307 shs
Average Volume
601,488 shs
Market Capitalization
$56.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.67
Consensus Rating
Buy

Company Overview

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Cytosorbents Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
52nd Percentile Overall Score

CTSO MarketRank™: 

Cytosorbents scored higher than 52% of companies evaluated by MarketBeat, and ranked 621st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytosorbents has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cytosorbents has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cytosorbents' stock forecast and price target.
  • Earnings Growth

    Earnings for Cytosorbents are expected to grow in the coming year, from ($0.30) to ($0.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytosorbents is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytosorbents is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cytosorbents has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cytosorbents' valuation and earnings.
  • Percentage of Shares Shorted

    2.65% of the outstanding shares of Cytosorbents have been sold short.
  • Short Interest Ratio / Days to Cover

    Cytosorbents has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Cytosorbents has recently increased by 3.57%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Cytosorbents does not currently pay a dividend.

  • Dividend Growth

    Cytosorbents does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.65% of the outstanding shares of Cytosorbents have been sold short.
  • Short Interest Ratio / Days to Cover

    Cytosorbents has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Cytosorbents has recently increased by 3.57%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Cytosorbents has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Cytosorbents this week, compared to 1 article on an average week.
  • Search Interest

    Only 5 people have searched for CTSO on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cytosorbents insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,313.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 6.60% of the stock of Cytosorbents is held by insiders.

  • Percentage Held by Institutions

    Only 32.87% of the stock of Cytosorbents is held by institutions.

  • Read more about Cytosorbents' insider trading history.
Receive CTSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

CTSO Stock News Headlines

StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
CytoSorbents opens regional sales subsidiary in Dubai
CytoSorbents sees Q4 product revenue $9M-$9.2M vs. $7.35M last year
See More Headlines

CTSO Stock Analysis - Frequently Asked Questions

Cytosorbents' stock was trading at $0.91 at the beginning of 2025. Since then, CTSO stock has increased by 14.3% and is now trading at $1.04.
View the best growth stocks for 2025 here
.

Cytosorbents Co. (NASDAQ:CTSO) released its quarterly earnings data on Thursday, November, 7th. The medical research company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.03. The medical research company had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.14 million. Cytosorbents had a negative net margin of 49.47% and a negative trailing twelve-month return on equity of 118.54%.

Cytosorbents' top institutional investors include Sargent Investment Group LLC (2.28%). Insiders that own company stock include Phillip P Chan, Vincent Capponi, Peter J Mariani, Al Kraus, Alan D Sobel, Michael G Bator, Edward Raymond Jones, Jiny Kim and Kathleen P Bloch.
View institutional ownership trends
.

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytosorbents investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Corning (GLW), UnitedHealth Group (UNH) and DocuSign (DOCU).

Company Calendar

Last Earnings
11/07/2024
Today
1/27/2025
Next Earnings (Estimated)
3/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:CTSO
Employees
220
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.67
High Stock Price Target
$10.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+348.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-28,510,000.00
Pretax Margin
-51.62%

Debt

Sales & Book Value

Annual Sales
$36.35 million
Book Value
$0.52 per share

Miscellaneous

Free Float
51,071,000
Market Cap
$56.87 million
Optionable
Optionable
Beta
0.58

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:CTSO) was last updated on 1/27/2025 by MarketBeat.com Staff
From Our Partners